⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BHVN News
Biohaven Ltd.
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
prnewswire.com
BHVN
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
prnewswire.com
BHVN
Belhaven Announces Significant Expansion of Nasdepi Patent Portfolio, Commercial Supply Readiness, and FDA Alignment on Key Topics
accessnewswire.com
BHVN
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
globenewswire.com
BHVN
AGIO
Form 8-K
sec.gov
BHVN
Biohaven Announces Scientific Leadership Transitions
prnewswire.com
BHVN
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
prnewswire.com
BHVN
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
prnewswire.com
BHVN
Form 8-K
sec.gov
BHVN